IOBT
IO Biotech, Inc.·Healthcare
0.01
27.588%(−0.00)
Market ClosedLast Updated: — ET
52W L: $0.0152W H: $2.79
IOBT NEWS
defenseworld.net
Mar 27
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received a consensus rating of "Reduce" from the five research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average twelve-month price target
defenseworld.net
Mar 2
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 4,262,939 shares, a drop of 20.9% from the January 29th total of 5,390,908 shares. Approximately 6.1% of the company's stock are sold short. Based on an
zacks.com
Feb 13
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
defenseworld.net
Feb 1
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Grows By 47.2%
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,083,794 shares, an increase of 47.2% from the December 31st total of 2,094,316 shares. Currently, 4.4% of the company's shares are sold short.
globenewswire.com
Jan 30
IO Biotech Provides Corporate Update
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic alternatives.
globenewswire.com
Jan 21
IO Biotech Announces Exploration of Strategic Alternatives
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution.
